Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanny Al-Samkari

Showing results (11-20 of 200) with videos related to

Pageof 20
Sort By:
JAMA|March 18, 2021
Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19Hanny Al-Samkari
Blood|December 23, 2021
Platelet clump visible to the naked eye in type 2B von Willebrand diseaseHanny Al-Samkari
Journal of Thrombosis and Haemostasis : JTH|January 31, 2025
Reuse, recycle, repurpose: pazopanib for bleeding in hereditary hemorrhagic telangiectasiaHanny Al-Samkari
Journal of Internal Medicine|August 23, 2023
Even effective drugs require adequately powered trials: Systemic bevacizumab in hereditary hemorrhagic telangiectasiaHanny Al-Samkari
Transplantation and Cellular Therapy|April 27, 2024
Thrombopoietin Agonism to Promote Platelet Engraftment Following Hematopoietic Stem Cell Transplantation: Promising, but Not Ready for PrimetimeHanny Al-Samkari
Blood Reviews|November 1, 2023
Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonistsHanny Al-Samkari
British Journal of Haematology|December 6, 2020
New therapeutic horizons in Wiskott-Aldriech syndromeHanny Al-Samkari
Research and Practice in Thrombosis and Haemostasis|September 2, 2025
Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?Hanny Al-Samkari
Thrombosis Research|July 31, 2022
Splanchnic vein thrombosis in the patient with cirrhosis: Better anticoagulated than not (for most patients)Hanny Al-Samkari
The Lancet. Haematology|June 25, 2021
Giving hereditary haemorrhagic telangiectasia the attention it deservesHanny Al-Samkari
Pageof 20

Showing results (11-20 of 200) with videos related to

Sort By:
Pageof 20
JAMA|March 18, 2021
Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19Hanny Al-Samkari
Blood|December 23, 2021
Platelet clump visible to the naked eye in type 2B von Willebrand diseaseHanny Al-Samkari
Journal of Thrombosis and Haemostasis : JTH|January 31, 2025
Reuse, recycle, repurpose: pazopanib for bleeding in hereditary hemorrhagic telangiectasiaHanny Al-Samkari
Journal of Internal Medicine|August 23, 2023
Even effective drugs require adequately powered trials: Systemic bevacizumab in hereditary hemorrhagic telangiectasiaHanny Al-Samkari
Transplantation and Cellular Therapy|April 27, 2024
Thrombopoietin Agonism to Promote Platelet Engraftment Following Hematopoietic Stem Cell Transplantation: Promising, but Not Ready for PrimetimeHanny Al-Samkari
Blood Reviews|November 1, 2023
Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonistsHanny Al-Samkari
British Journal of Haematology|December 6, 2020
New therapeutic horizons in Wiskott-Aldriech syndromeHanny Al-Samkari
Research and Practice in Thrombosis and Haemostasis|September 2, 2025
Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?Hanny Al-Samkari
Thrombosis Research|July 31, 2022
Splanchnic vein thrombosis in the patient with cirrhosis: Better anticoagulated than not (for most patients)Hanny Al-Samkari
The Lancet. Haematology|June 25, 2021
Giving hereditary haemorrhagic telangiectasia the attention it deservesHanny Al-Samkari
Pageof 20